Deep and future insights into neuromodulation therapies for heart failure.
Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50%. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.
Department of Collaborative Research Institute of Innovation for Cardiovascular Diseases, Kyushu University Center for Disruptive Cardiovascular Medicine, Fukuoka, Japan. Electronic address: tkishi@cardiol.med.kyushu-u.ac.jp.
Takuya
T
Kishi
D017704:Baroreflex / Q000502:physiology; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D062187:Spinal Cord Stimulation; D013562:Sympathectomy; D013564:Sympathetic Nervous System / Q000502:physiology; D055536:Vagus Nerve Stimulation
Baroreflex; Heart failure; Renal nerve; Sympathetic nerve; Vagal nerve